ABLYNX RESPONDS TO PRESS REPORTS
(Thomson Reuters ONE) -
THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE
UNITED STATES, CANADA, JAPAN AND AUSTRALIA
FOR IMMEDIATE RELEASE
GHENT, Belgium, 22 February, 2010 - Subsequent to various reports in the press,
Ablynx can confirm that it is considering raising additional funds through a
secondary public offering. No decision has been taken and any final decision to
initiate a capital raising will be made subject to market conditions and other
factors.
Ablynx is a biopharmaceutical company focused on the discovery and development
of Nanobodies, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious and life-threatening human diseases.
There are four Nanobody-based products currently undergoing clinical trials.
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on the discovery and development of Nanobodies, a novel class of therapeutic
proteins based on single-domain antibody fragments, for a range of serious and
life-threatening human diseases. The Company currently has over 230 employees.
Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of
major disease areas, including inflammation, thrombosis, oncology and
Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic
pipeline including four Nanobodies in clinical development. So far, Nanobodies
have been successfully generated against more than 190 different protein targets
including several complex targets such as chemokines, GPCRs, ion channels and
viruses, which are typically very difficult to approach with conventional
monoclonal antibodies. Efficacy data have been obtained in 28 in vivo models for
Nanobodies against a range of different targets.
Ablynx has an extensive patent position in the field of Nanobodies for
healthcare applications. It has exclusive and worldwide rights to more than 130
families of granted patents and pending patent applications, including the
Hamers patents covering the basic structure, composition, preparation and uses
of Nanobodies.
For more information, please contact:
Contacts at Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
+44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 08
e: wim.ottevaere(at)ablynx.com
[HUG#1387199]
Complete version of the press release: http://hugin.info/137912/R/1387199/345578.pdf
Unternehmensinformation / Kurzprofil:
Datum: 22.02.2010 - 21:46 Uhr
Sprache: Deutsch
News-ID 12817
Anzahl Zeichen: 0
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX RESPONDS TO PRESS REPORTS"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
